The world's fastest LCMS/MS tandem mass spectrometer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The world's fastest LCMS/MS tandem mass spectrometer


Expanded range of ultra-fast, high-sensitivity applications

Shimadzu’s LCMS-8040 combines newly improved ion optics and collision cell technology with proprietary ultrafast technologies. This significantly expands the application range and ensures high-sensitivity, high-throughput analysis at lower levels of detection.

A five-fold increase in sensitivity (reserpine, S/N ratio) has been achieved in comparison to the LCMS-8030 model by improving ion focusing and minimizing ion losses between multi-pole lenses.

The fastest scan speed of 15,000 u/s and the fastest polarity switching time of 15 msec, already known from the LCMS-8030, expand in combination with the higher sensitivity the potential range of LC/MS/MS applications. The LCMS-8040 achieves multiple reaction monitoring (MRM) transition speeds of up to 555 MRMs per second utilizing UFsweeper II collision cell technology. UFsweeper II features high-speed ion transport technology that maintains sensitivity and suppresses crosstalk, even for high-speed or simultaneous multi-component analyses.

LabSolutions LCMS software offers a variety of data processing features, including a Quantitation Browser which processes multiple analytes, and a Data Browser which allows users to analyze and compare multiple sets of data in the same window.

For more information please visit www.shimadzu.eu.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here